Juvenile idiopathic arthritis - PubMed (original) (raw)

Review

Juvenile idiopathic arthritis

Angelo Ravelli et al. Lancet. 2007.

Abstract

Juvenile idiopathic arthritis is a broad term that describes a clinically heterogeneous group of arthritides of unknown cause, which begin before 16 years of age. This term encompasses several disease categories, each of which has distinct methods of presentation, clinical signs, and symptoms, and, in some cases, genetic background. The cause of disease is still poorly understood but seems to be related to both genetic and environmental factors, which result in the heterogeneity of the illness. Although none of the available drugs has a curative potential, prognosis has greatly improved as a result of substantial progresses in disease management. The most important new development has been the introduction of drugs such as anticytokine agents, which constitute a valuable treatment option for patients who are resistant to conventional antirheumatic agents. Further insights into the disease pathogenesis and treatment will be provided by the continuous advances in understanding of the mechanisms connected to the immune response and inflammatory process, and by the development of new drugs that are able to inhibit selectively single molecules or pathways.

PubMed Disclaimer

Comment in

Complementary therapies in juvenile idiopathic arthritis.
Kemper KJ, Rouster-Stevens K, Sinal S, Arcury T. Kemper KJ, et al. Lancet. 2007 May 12;369(9573):1602. doi: 10.1016/S0140-6736(07)60746-6. Lancet. 2007. PMID: 17499601 No abstract available.

Cited by

Juvenile idiopathic arthritis in Harlequin ichthyosis, a rare combination or the clinical spectrum of the disease? Report of a child treated with etanercept and review of the literature.
Baldo F, Brena M, Carbogno S, Minoia F, Lanni S, Guez S, Petaccia A, Agostoni C, Cimaz R, Filocamo G. Baldo F, et al. Pediatr Rheumatol Online J. 2021 Jun 3;19(1):80. doi: 10.1186/s12969-021-00571-9. Pediatr Rheumatol Online J. 2021. PMID: 34082764 Free PMC article. Review.
Update on the management of uveitis in children: an overview for the clinician.
Kim L, Li A, Angeles-Han S, Yeh S, Shantha J. Kim L, et al. Expert Rev Ophthalmol. 2019;14(4-5):211-218. doi: 10.1080/17469899.2019.1663731. Epub 2019 Sep 19. Expert Rev Ophthalmol. 2019. PMID: 32831897 Free PMC article.
Independent confirmation of juvenile idiopathic arthritis genetic risk loci previously identified by immunochip array analysis.
Chiaroni-Clarke RC, Munro JE, Chavez RA, Pezic A, Allen RC, Akikusa JD, Piper SE, Saffery R, Ponsonby AL, Ellis JA. Chiaroni-Clarke RC, et al. Pediatr Rheumatol Online J. 2014 Dec 16;12:53. doi: 10.1186/1546-0096-12-53. eCollection 2014. Pediatr Rheumatol Online J. 2014. PMID: 25540605 Free PMC article.
Effect of probiotics on clinical and immune parameters in enthesitis-related arthritis category of juvenile idiopathic arthritis.
Shukla A, Gaur P, Aggarwal A. Shukla A, et al. Clin Exp Immunol. 2016 Sep;185(3):301-8. doi: 10.1111/cei.12818. Clin Exp Immunol. 2016. PMID: 27238895 Free PMC article. Clinical Trial.
Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis.
Alberdi-Saugstrup M, Nielsen S, Mathiessen P, Nielsen CH, Müller K. Alberdi-Saugstrup M, et al. Clin Rheumatol. 2017 Jan;36(1):67-75. doi: 10.1007/s10067-016-3375-x. Epub 2016 Aug 25. Clin Rheumatol. 2017. PMID: 27562034

Juvenile idiopathic arthritis - PubMed (original) (raw)